Hypoxia Drives Breast Cancer Immune Escape Through FTO Epigenetic Pathway
A newly identified HIF-1α/FTO/PDK1/PD-L1 axis lets breast cancer cells hide from immune attack under low oxygen—and blocking it boosts immunotherapy.
Résumé
Researchers discovered that oxygen-starved breast cancer cells activate the RNA demethylase FTO via HIF-1α, triggering a cascade that stabilizes PDK1 mRNA by stripping m6A marks, preventing YTHDF3-mediated degradation. Elevated PDK1 then activates AKT/STAT3 signaling to upregulate PD-L1, shielding tumors from immune attack. Blocking FTO with FB23 or PDK1 with BX-912—alone or combined with the PD-L1 inhibitor Atezolizumab—suppressed tumor growth, boosted cytotoxic T-cell activity, and improved immunotherapy response in mouse models. The findings suggest dual targeting of FTO and PDK1 may overcome immunotherapy resistance in breast cancer.
Résumé détaillé
Breast cancer frequently evades immunotherapy by upregulating PD-L1, particularly in the hypoxic tumor microenvironment. Although immune checkpoint inhibitors targeting PD-1/PD-L1 have shown promise in triple-negative breast cancer, most patients do not benefit, and the epigenetic mechanisms linking hypoxia to immune evasion remained poorly understood. This study aimed to fill that gap by mapping how the RNA demethylase FTO connects hypoxic stress to PD-L1 overexpression.
The investigators first established that HIF-1α directly binds the FTO promoter and transcriptionally activates it under 1% O2 conditions, a finding validated in clinical breast cancer specimens and TCGA data showing FTO overexpression correlates with worse outcomes and reduced CD8+ T-cell infiltration. To identify downstream targets, the team performed MeRIP-seq and mRNA-seq on hypoxic breast cancer cells, revealing PDK1 as a key m6A-regulated gene. FTO erases m6A marks on PDK1 mRNA, preventing the reader protein YTHDF3 from recognizing and degrading it, thus stabilizing PDK1 transcript and boosting PDK1 protein levels.
Elevated PDK1 was shown to phosphorylate and activate AKT, which in turn activates STAT3 to transcriptionally upregulate CD274 (PD-L1). This mechanistic chain was validated through sequential knockdown and overexpression experiments across MDA-MB-231, MCF-7, and 4T1 cell lines, m6A-RIP qPCR confirming reduced PDK1 m6A methylation when FTO is overexpressed, and RNA stability assays demonstrating accelerated PDK1 mRNA decay upon YTHDF3 binding.
In syngeneic BALB/c mouse models bearing 4T1 tumors, oral FB23 (FTO inhibitor) and BX-912 (PDK1 inhibitor) each suppressed tumor growth, while their combination with intraperitoneal Atezolizumab produced additive anti-tumor effects, enhanced intratumoral cytotoxic T lymphocyte infiltration, and reduced regulatory T-cell populations measured by flow cytometry. Clinical samples from patients receiving neoadjuvant Adebrelimab showed that high FTO/PDK1 co-expression associated with non-pathologic complete response, supporting translational relevance.
Collectively, the study establishes a hypoxia-driven HIF-1α → FTO → m6A/YTHDF3 → PDK1 → AKT/STAT3 → PD-L1 axis as a targetable immunosuppressive pathway in breast cancer and provides preclinical evidence that combining FTO or PDK1 inhibition with PD-L1 blockade may overcome checkpoint inhibitor resistance.
Principales conclusions
- HIF-1α directly transcribes FTO under hypoxia, linking oxygen deprivation to m6A erasure in breast cancer cells.
- FTO removes m6A marks from PDK1 mRNA, blocking YTHDF3-mediated degradation and raising PDK1 protein levels.
- Elevated PDK1 activates AKT/STAT3 signaling, driving PD-L1 upregulation and tumor immune evasion.
- FTO inhibitor FB23 plus PDK1 inhibitor BX-912 synergized with Atezolizumab to suppress tumors and restore CTL activity in mice.
- High FTO/PDK1 expression in patient biopsies correlated with failure to achieve pathologic complete response to PD-L1-based neoadjuvant therapy.
Méthodologie
The study combined MeRIP-seq and mRNA-seq in hypoxic breast cancer cell lines to map m6A-regulated transcripts, validated mechanistic links via ChIP, RIP-qPCR, RNA stability assays, and luciferase reporters, and tested therapeutic combinations in syngeneic BALB/c mouse models with flow cytometric immune profiling. Clinical correlation used archived IHC specimens from two independent hospital cohorts plus TCGA bioinformatics.
Limites de l'étude
In vivo work relied on immunocompetent syngeneic mouse models with murine 4T1 cells, which may not fully recapitulate human tumor-immune interactions. The clinical cohort for neoadjuvant therapy response was small and retrospective. Long-term safety and pharmacokinetics of combined FTO/PDK1 plus checkpoint inhibitor regimens in humans remain untested.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :